View More Recent Stories

Sep 4, 2024 08:35AM Outlook Therapeutics (OTLK) Announces Completion of Enrollment in NORSE EIGHT Clinical Trial
Aug 14, 2024 10:59AM Outlook Therapeutics, Inc. (OTLK) Tops Q2 EPS by 9c
Jul 8, 2024 08:35AM Outlook Therapeutics (OTLK) Announces UK MHRA Marketing Authorization of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
View More Recent Stories